Research Desk Line-up: China Biologic Products Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for MannKind Corp. (NASDAQ: MNKD), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MNKD. The Company and One Drop announced on August 07, 2017, the first step of their collaboration with the launch of A-ONE study, a randomized controlled trial investigating the use of Afrezza inhaled insulin and One Drop's integrated digital diabetes care platform. One Drop is a unique, fully integrated solution with the prospects of a huge health benefit. The combination of One Drop with inhaled insulin is expected to offer consumers, health care providers, and payers a potentially powerful solution with unprecedented benefits. One Drop, also known as Informed Data Systems, Inc., is a digital health Company, leveraging the power of mobile computing and data science to transform the lives of people with diabetes. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected China Biologic Products Holdings, Inc. (NASDAQ: CBPO) for due-diligence and potential coverage as the Company announced on August 02, 2017, its unaudited financial results for Q2 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on China Biologic Products when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MNKD; also brushing on CBPO. Go directly to your stock of interest and access today's free coverage at:
This announcement comes at the heels of the May 2017 release, where MannKind and One Drop announced a memorandum of understanding to explore collaborations related to One Drop and Afrezza, MannKind's inhaled rapid-acting mealtime insulin. The primary goal of the collaboration is to identify ways to simplify the complexity of starting and staying on mealtime insulin along with customized coaching to help people achieve their A1C goals.
Under the A-ONE study, appropriate people with type-2 diabetes who meet inclusion criteria will be randomized to one of two treatment terms: Afrezza® with One Drop | Premium — or — One Drop | Premium alone. Changes in hemoglobin A1C, self-care, treatment satisfaction, quality of life, and other metrics will be assessed too, under the study. The Company expects to deliver improved health outcomes at a fraction of the cost of current standards of care, where it is set to evaluate whether a completely integrated digital diabetes therapeutics platform coupled with MannKind's Afrezza could deliver a feasible, low-cost solution.
H1 2017 Results
MannKind reported net revenues of $5.2 million for the six-month period ended June 30, 2017. The Company announced $2.7 million of Afrezza product sales and $1.8 million from the sale of surplus bulk insulin to a third party and $0.6 million from the sale of certain oncology property in H1 2017. The Company reported net loss of $51.7 million for the six months ended June 30, 2017, versus net loss of $54.8 million for the period ended June 30, 2016.
Q2 2017 Results
MannKind reported its Q2 2017 results on August 07, 2017, for the three-month period ended June 30, 2017. The Company reported total net revenue of $2.2 million in Q2 2017, which was comprised of $1.5 million of Afrezza product's net sales, $0.1 million of collaboration revenues, and $0.6 million of other revenues from the sale of certain oncology intellectual property. As of June 30, 2017, Afrezza, which was shipped to the wholesale and retail channel, is not yet recognized as revenue was $2.6 million.
The net revenue and gross revenue from Afrezza advanced 29% and 60%, respectively, in Q2 2017 versus Q1 2017. The Company reported net loss of $35.3 million, or $0.35 per share, in Q2 2017 against net loss of $30.0 million in Q2 2016. During the quarter, MannKind also reduced its Deerfield obligations by $15 million through equity conversion and cash payments and held a positive pre-IND meeting with the FDA for treprostnil Technosphere, a potential treatment of pulmonary arterial hypertension with the intention of filing an investigational new drug application by the end of 2017.
Last Close Stock Review
At the closing bell, on Tuesday, August 08, 2017, MannKind's stock declined 1.71%, ending the trading session at $1.15. A total volume of 2.03 million shares have exchanged hands. The Company's stock price advanced 2.68% in the last three months. The stock is trading at a PE ratio of 0.84 and currently, has a market cap of $112.35 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily